192 related articles for article (PubMed ID: 32632941)
41. Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Murray LJ; Dawson LA
Semin Radiat Oncol; 2017 Jul; 27(3):247-255. PubMed ID: 28577832
[TBL] [Abstract][Full Text] [Related]
42. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
Rim CH; Lee HY; Kim JS; Kim H
Int J Radiat Biol; 2021; 97(2):111-119. PubMed ID: 33253598
[TBL] [Abstract][Full Text] [Related]
43. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities.
Soni PD; Palta M
Dig Dis Sci; 2019 Apr; 64(4):1008-1015. PubMed ID: 30868409
[TBL] [Abstract][Full Text] [Related]
44. Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives.
Doi H; Beppu N; Kitajima K; Kuribayashi K
Anticancer Res; 2018 Feb; 38(2):591-599. PubMed ID: 29374681
[TBL] [Abstract][Full Text] [Related]
45. Advances in external beam stereotactic body radiotherapy: principle concerns in implementing a liver radiation program.
Gaede S; Lock MI
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S13. PubMed ID: 28917251
[TBL] [Abstract][Full Text] [Related]
46. Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant.
Valakh V; Gresswell S; Kirichenko A
Anticancer Res; 2018 Dec; 38(12):6815-6820. PubMed ID: 30504395
[TBL] [Abstract][Full Text] [Related]
47. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
Lo CH; Lee HL; Hsiang CW; Chiou JF; Lee MS; Chen SW; Shen PC; Lin CS; Chang WC; Yang JF; Dai YH; Chen CY; Chia-Hsien Cheng J; Huang WY
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):474-484. PubMed ID: 32898609
[TBL] [Abstract][Full Text] [Related]
48. Proton Beam Therapy in Liver Malignancies.
Siddiqui O; Pollock A; Samanta S; Kaiser A; Molitoris JK
Curr Oncol Rep; 2020 Feb; 22(3):30. PubMed ID: 32108284
[TBL] [Abstract][Full Text] [Related]
49. Evolution of Response-Based Radiotherapy for Hepatocellular Cancer.
Elaimy AL; Cao Y; Lawrence TS
Cancer J; 2023 Sep-Oct 01; 29(5):266-271. PubMed ID: 37796644
[TBL] [Abstract][Full Text] [Related]
50. The role of external beam radiotherapy in the treatment of hepatocellular cancer.
Chino F; Stephens SJ; Choi SS; Marin D; Kim CY; Morse MA; Godfrey DJ; Czito BG; Willett CG; Palta M
Cancer; 2018 Sep; 124(17):3476-3489. PubMed ID: 29645076
[TBL] [Abstract][Full Text] [Related]
51. Role of External Beam Radiotherapy in Hepatocellular Carcinoma.
Chen CP
Clin Liver Dis; 2020 Nov; 24(4):701-717. PubMed ID: 33012454
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration.
Lee S; Kim H; Ji Y; Cho B; Kim SS; Jung J; Kwak J; Park JH; Lee SW; Kim JH; Yoon SM
Sci Rep; 2018 Nov; 8(1):16224. PubMed ID: 30385839
[TBL] [Abstract][Full Text] [Related]
53. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
54. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints.
Park S; Yoon WS; Rim CH
World J Gastroenterol; 2020 Jan; 26(4):393-403. PubMed ID: 32063688
[TBL] [Abstract][Full Text] [Related]
55. An overview of stereotactic body radiation therapy for hepatocellular carcinoma.
Kimura T; Doi Y; Takahashi S; Kubo K; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Murakami Y; Kenjo M; Nagata Y
Expert Rev Gastroenterol Hepatol; 2020 Apr; 14(4):271-279. PubMed ID: 32223683
[No Abstract] [Full Text] [Related]
56. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
Sanuki N; Takeda A; Oku Y; Mizuno T; Aoki Y; Eriguchi T; Iwabuchi S; Kunieda E
Acta Oncol; 2014 Mar; 53(3):399-404. PubMed ID: 23962244
[TBL] [Abstract][Full Text] [Related]
57. Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review.
Glicksman RM; Tjong MC; Neves-Junior WFP; Spratt DE; Chua KLM; Mansouri A; Chua MLK; Berlin A; Winter JD; Dahele M; Slotman BJ; Bilsky M; Shultz DB; Maldaun M; Szerlip N; Lo SS; Yamada Y; Vera-Badillo FE; Marta GN; Moraes FY
JAMA Oncol; 2020 Apr; 6(4):567-577. PubMed ID: 31895403
[TBL] [Abstract][Full Text] [Related]
58. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
[TBL] [Abstract][Full Text] [Related]
59. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
[TBL] [Abstract][Full Text] [Related]
60. Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience.
Wigg AJ; Narayana SK; Le H; Iankov I; Chinnaratha MA; Tse E; Chen JW; Gowda R
ANZ J Surg; 2019 Sep; 89(9):1138-1143. PubMed ID: 30983104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
